Published On: Thu, Mar 2nd, 2017

Shares Of Horizon Discovery Group (LON:HZD) Rated As Buy By Analysts At Numis Securities

According to an update released by analysts at Numis Securities the broker has now set a ‘Buy’ rating on shares of Horizon Discovery Group (LON:HZD) with a price target of 262.

Numis Securities on Thursday reiterated Horizon Discovery Group’s analyst rating as ‘Buy’ with its price target of 262 highlighting a potential increase of 60.24% from Horizon Discovery Group’s current price of 163.5.


Over the last twelve months Horizon Discovery Group’s stock price has increased from 151.5 to 163.5, a change of 7.92%.

Horizon Discovery Group has 94,122,000 shares in issue which have a share price of 163.5 giving Horizon Discovery Group a market capitalisation of 153.89M GBp.

The company has a 50 day moving average of 172.79 and a 200 day moving average of 151.31. The 52 week high shares of Horizon Discovery Group have reached is 188.06 whilst the 52 week low for the company’s shares is 104.

Horizon Discovery Group PLC is a gene editing company that designs and engineers genetically-modified cells, applying them in research and clinical applications to advance human health. The Company’s gene editing platform, able to alter almost any gene sequence, has generated a catalogue of over 23,000 cell and in vivo models that recapitulate the genetic anomalies found in diseases like cancer. These models have been adopted by c1,400 organizations to better understand of the genetic drivers of disease, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline.